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a b s t r a c t
Complex regional pain syndrome (CRPS) is a descriptive term for a complex of symptoms
and signs typically occurring following trauma of the extremity. Typical symptomatology
includes severe pain, swelling, vasomotor instability and functional impairment of the
affected limb. At present there is no one, effective method of treatment of the condition. A
large number of treatments have been investigated but major multicentre randomized
controlled trials are lacking. This study presents the results of a systematic review of the
evidence on effectiveness of treatment methods in CRPS.
It is a follow-up to earlier reviews of randomized controlled trials on CRPS treatment
published between 1966 and 2016. Results. The review of randomized controlled trials
showed that only bisphosphonates were found to give uniformly positive effects, statisti-
cally signiﬁcantly better than placebo. Improvement has been reported with topical dimeth-
yl sulfoxide, systemic steroids, spinal cord stimulation and graded motor imagery/mirror
therapy programmes. The available evidence does not support the use of other treatments in
CRPS, however they are frequently used in clinical practice.
Conclusion: Available evidence, although numerous, does not necessarily reﬂect what is
truly effective and what is sham in the management of CRPS.
© 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Complex regional pain syndrome (CRPS) is a complex of
symptoms typically occurring following trauma of the ex-
tremity. At present the ‘‘Budapest criteria’’ for diagnosis are
commonly accepted and frequently used in scientiﬁc studies
although subjective and open to exaggeration [1]. There is no* Corresponding author.
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diagnosis relies on clinical assessment with the requirement
for a sufﬁcient number of symptoms and signs to be present. A
lack of understanding of the underlying pathophysiology for
CRPS contributes to the difﬁculty in developing deﬁnitive
treatments. A large number of treatments have been investi-
gated but major multicentre randomized controlled trials are
lacking and the primary outcome parameters (pain, function).poczta.pl (P. Puchalski).
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tal role of early therapeutic intervention as it may prevent the
disease transition from acute to a chronic form, although it is
not yet proven how this changes the course of CRPS [2].
2. Methods
This systematic review is a follow-up to earlier reviews of
randomized controlled trials (RCTs) of CRPS treatment
published between 1966 and 2014. Five studies were consid-
ered and used in this analysis:
 Review of 18 RCTs published from 1966 to 2000 [3].
 Review of 21 RCTs published from 1980 to 2000 [4].
 Review of 35 RCTs published from 1980 to 2005 [5].
 Review of 41 RCTs published from 1950 to 2009 [6].
 Review of 29 RCTs published from 2000 to 2012 [7].
Three other reviews of randomized, controlled trials that
focused on speciﬁc CRPS treatments, published between 2012
and 2016 were analyzed:
 Review of 18 RCTs focused on physiotherapy, published
from 1999 to 2014 [8].
 Review of 3 RCTs focused on ketamine infusions, published
from 1999 to 2014 [9].
 Review of 12 RCT focused on the efﬁcacy of local anaesthetic
sympathetic blocks, published from 2005 to 2015 [10].
No other, relevant studies have been found up to the
completion of this review in October 2017.
In this review CRPS is considered ‘‘early’’ when it had lasted
less than 6 months or ‘‘chronic’’ (long-standing) when it had
lasted more than 6 months. It is likely these criteria will
change as diagnosis becomes swifter and more reliable not
least as 6 months is quite late to initiate treatment.
3. Results
The following therapeutic interventions were assessed in
these studies.
3.1. Calcitonin
It has been used in CRPS because of its analgesic properties
through release of b-endorphin in the central nervous system
and its inhibition of bone resorption. Four RCTs investigated
the effect of calcitonin in a nasal spray (three) or subcutaneous
(s.c.) injections (one) in the treatment of 163 patients with
acute and chronic CRPS. Nasal calcitonin spray was adminis-
tered in doses of 200–400 U/day for 3–4 weeks, whereas s.c.
calcitonin 100 U/day was given for 8 weeks. In two studies,
calcitonin was combined with an intensive physiotherapy
regimen, which was the same in the treatment and placebo
groups. All but one trial were small, including fewer than 30
patients in one study arm. At a mean follow-up of 2 (range 1–2)
months, statistically signiﬁcant differences were noted in pain
scores (using a four-point pain scale) and in ranges of motion,favouring the treatment (nasal calcitonin, 300 U/day for 3
weeks) group in one study [11]. The other studies showed no
intergroup differences in terms of pain relief, improvement of
ranges of motion and grip strength, reduction of oedema,
stiffness or vasomotor changes [6,7,12]. There is conﬂicting
evidence with respect to the efﬁcacy of calcitonin for the
treatment of CRPS. This treatment is relatively simple, safe
and therefore frequently used in clinical practice. Its efﬁcacy is
conﬁned to early CRPS i.e. lasting less than 6 months. One
disadvantage of use calcitonin is intolerance which occurs in
about 30% of patients; in particular they may experience
unpleasant adverse symptoms during ﬁrst 1–2 days of
calcitonin administration.
3.2. Bisphosphonates
They have been used in CRPS because of their potential to
inhibit bone resorption. Four RCTs investigated the effect of
bisphosphonates in a total of 118 patients with acute and
chronic CRPS (duration 3 to 22 months) affecting the upper or
lower limb. Three types of bisphosphonates: alendronate,
pamidronate and clodronate were used in i.v. infusions (three)
or orally (one). Alendronate 7.5 mg/day was administered
intravenously (i.v.) for 3 days and after 14 days [13];
alendronate 40 mg/day was administered orally for 8 weeks
followed by 4 weeks nontherapeutic period and 8 weeks open
extension [14]; clodronate 300 mg/day was administered i.v.
for 10 days [15]; pamidronate 60 mg was given in single i.v.
infusion [16]. In all studies drug therapy was combined with
formal physiotherapy. At a mean follow-up of 6 (range 1–13)
months, all four studies showed statistically signiﬁcant
differences in pain relief, improvement of function and overall
improvement favouring the treatment groups.
In one trial bisphosphonate (parecoxib) combined with
clonidine and lidocaine was given in a regional intravenous
regional block (Bier block). This therapy decreased pain more
than either i.v. parecoxib with regional lidocaine and cloni-
dine, or a control group, without bisphosphonate [17].
There is not strong evidence for the efﬁcacy of bispho-
sphonates, with no high-quality trials although positive
ﬁndings from one on i.v. pamidronate and one on oral
alendronate. Oral alendronate administered in high dose is
not licensed in some countries. The trials differed with regard
to disease duration and included patients with early and
chronic CRPS. In spite of positive but not very strong evidence
for the effectiveness of this therapy, it is not frequently used in
clinical practice. Two ongoing trials should be published in
2017/2018 providing further evidence.
3.3. Free radical scavengers
They have been used in CRPS because of their anti-inﬂamma-
tory potential. This therapy is based on the assumption that
CRPS is caused by an exaggerated inﬂammatory response to
trauma, mediated by an overproduction of toxic oxygen and
hydroxyl free radicals. Four RCTs investigated the effect of
these drugs involving 210 patients with acute and chronic
CRPS [18–21]. Three free radical scavengers were used:
dimethyl sulfoxide (DMSO) (topical for 2 months), N-acet-
ylcysteine (oral for 4 months) and mannitol (i.v. for 5 days). In
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 3 2 6 – 3 3 3328one study, the intervention (topical DMSO for 3 weeks) was
compared to another intervention – intravenous regional
blockade with guanethidine (twice per week for three weeks)
[18] and in the other study, two interventions were compared,
topical DMSO vs oral N-acetylcysteine, both for 4 months [19].
The others were compared against placebo. In all studies drug
therapy was combined with formal physiotherapy. At a mean
follow-up of 4 (range 2–12) months follow-up statistically
signiﬁcant differences were noted in a scoring system based
on pain, disability, oedema, skin colour and ranges of motion,
favouring treatment with DMSO vs guanethidine in one study.
This study involved only patients with early CRPS, lasting <3
months [18]. The other studies showed no intergroup differences
in terms of pain relief, improvement of ranges of motion and grip
strength or reduction of other features of CRPS.
There is moderate evidence for the effectiveness of topical
50% DMSO cream in reducing the symptoms of early CRPS.
Likewise, there is moderate evidence for the effectiveness of
oral N-acetylcysteine in reducing the symptoms of chronic
CRPS. Free radical scavengers have been used frequently in
clinical practice, mostly in the Netherlands.
3.4. Intravenous regional sympathectomy
This therapy is based on the assumption that CRPS is
associated with a dysfunction of the sympathetic nervous
system. Thus, sympathetic interruption using intravenous
regional blocks (Bier blocks) consisting of local anaesthetic and
an anti-sympathetic drug might have a beneﬁcial effect. Five
RCTs have investigated the effect of this therapy, involving a
total of 101 patients with acute and chronic CRPS [22–26]. Three
drugs were tested: guanethidine (an inhibitor of the presyn-
aptic release of norepinephrine; three trials); droperidol (an
alpha adrenergic antagonist; one trial); and ketanserin (a
serotonin type 2 receptor antagonist; one trial). In three studies
the active drugs and placebo were diluted in normal saline and
in one study the drug (guanethidine) and placebo were diluted
in 0.5% prilocaine [24]. The treatment consisted of 2–4 blocks
administered at weekly intervals. In all studies drug therapy
was combined with formal physiotherapy. At a mean follow-
up of 9 (range 1–24) weeks follow-up no beneﬁts were found
from adding intravenous regional anti-sympathetic compar-
ing to intravenous regional saline or prilocaine (placebo).
There is relatively weak evidence for the effectiveness of i.v.
regional sympathectomy for treatment of CRPS. At present this
treatment is not popular and, if used, is conﬁned to patients
responding positively to a phentolamine test.
Two other RCTs compared different anti-sympathetic
modalities: regional intravenous blocks with guanethidine
vs regional intravenous blocks with reserpine (an agent
inhibiting norepinephrine synthesis and depleting norepi-
nephrine stores) vs plain 1% lidocaine; and regional intrave-
nous blocks with guanethidine vs stellate ganglion blocks with
lidocaine [27,28]. In the former study, every subject underwent
treatment with all three solutions in a randomized fashion at
weekly intervals. Both trials were small, including 12 and nine
patients respectively.
At mean follow-ups of 24 and 2 months, respectively, no
signiﬁcant differences were noted between the treatment
groups in terms of pain relief and functional improvement.Three of 12 patients receiving guanethidine or reserpine blocks
obtained signiﬁcant pain relief lasting 12 months [28].
3.5. Sympathetic ganglion blocks
The stellate and lumbar sympathetic ganglia are responsible
for the sympathetic innervation of the upper and lower limbs,
respectively. Blocking of these ganglia results in inhibition of
sympathetic efferent action in the affected limb. Four RCTs
involving 90 patients with early and chronic CRPS investigated
the effect of sympathetic ganglion blocks. One low-quality RCT
involving seven patients with chronic CRPS investigated the
effect of sympathetic blocks performed with 1% lidocaine vs
normal saline for stellate ganglion blockade and with 0.125%
bupivacaine vs normal saline for lumbar sympathetic chain
blockade. The two therapeutic or saline blocks were separated
by an interval of 7–10 days. Immediately after the injections no
differences were found between the analgesic effects of the
two types of injection. The duration of pain relief was greater
with lidocaine/bupivacaine than saline blocks (5 days vs 12 h)
[29]. One high-quality RCT involving 15 patients with early
CRPS who responded to a single stellate ganglion block (>50%
pain relief) compared the effect of the addition of a series of
ﬁve stellate ganglion blockades over 1 month to a combination
of oral drug therapy and physiotherapy. At a follow-up of one
month after the last injection no intergroup differences were
observed [30]. One high-quality RCT involving 25 patients with
early and chronic CRPS compared the effect of three inter-
ventions: stellate ganglion block with 1% lidocaine (9 patients)
vs stellate ganglion ultrasound block (9 patients) and vs
stellate ganglion saline block (7 patients). A total of ten
therapeutic blocks with 1% lidocaine were performed. The
ultrasound block consisted of 5 min of intermittent ultrasound
application at 3 W/cm2 over the stellate ganglion. A total of ten
‘‘sham’’ saline blocks were performed. All groups had further
rehabilitation. At a follow-up all one month after the last
blockade, no intergroup differences in pain relief or functional
improvement were observed [31].
One high-quality RCT involving 43 patients with early and
chronic upper limb CRPS compared the effect of three
interventions: stellate ganglion block with 1% lidocaine (14
patients) vs stellate ganglion block with 1% lidocaine plus
30 mg clonidine (15 patients) and vs regional intravenous block
with 1% lidocaine plus 30 mg clonidine (14 patients). A series of
ﬁve stellate ganglion/regional intravenous blockades were
preformed at weekly intervals. At a follow-up all one month
after the last blockade, no intergroup differences in pain relief
or functional improvement were observed [32].
Other two low-quality RCTs involving 24 patients with
chronic lower limb CRPS investigated the effect of lumbar
sympathetic chain lesions with 7% phenol or thermal radio-
frequency application. At a mean follow-up of 3 (range 2–4)
months, a reduction in pain scores compared with baseline
was noted in both groups, but no intergroup differences were
observed [33,34].
Likewise with intravenous regional sympathectomy, there
is relatively weak evidence supporting the effectiveness of
sympathetic ganglion blocks in CRPS. At present this treat-
ment is rarely used, and, if so, mostly in patients with chronic
lower limb CRPS.
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They have been used in CRPS because of their anti-inﬂamma-
tory action. The underlying rationale was same as in use of free
radicals scavengers. Four RCTs investigated the effect of
steroids administered over a period form 4 to 12 weeks in 148
patients with chronic CRPS. In two of the studies the patients
had speciﬁc post-stroke CRPS (so called shoulder-hand
syndrome). Two of four trials were small, including 12 and
17 patients in one study arm [35,36]. Three types of steroids
were used: prednisone (10 mg/day orally until clinical re-
sponse or maximum of 12 weeks) [35] and methylprednisolone
(8 mg/day orally, then taper dose for two weeks) [36]; and in
one study involving 60 patients, prednisolone (40 mg/day
orally for two weeks tapering to a dose of 10 mg/week) was
compared with piroxicam 20 mg/day [37]. All these three trials
were of relatively low quality. Immediately after treatment
there were statistically signiﬁcant differences in pain relief,
reduction in signs of CRPS features and improvement
favouring the treatment groups in three trails. The results of
the most recent high-quality RCT, showed that the efﬁcacy of
60–100 mg oral prednisone administered for 2–3 weeks was
statistically signiﬁcant but limited in treating CRPS of more
than 3 months duration not responding to previous treatment
[38].
One high-quality RCT investigated the effect of three
regional intravenous blocks of 40 mg methylprednisolone in
10 ml of 2% lidocaine vs saline blocks, given as one block per
week for 3 weeks. At follow-up at 4 weeks therapeutic blocks
were no more effective than saline in treating early CRPS
[39].
In spite of relatively weak evidence for the effectiveness
of steroids for treatment of CRPS, they are frequently used in
clinical practice, especially in early CRPS (a error type I is
likely to be present) Steroids appear to be useful in chronic
CRPS for patients after stroke, but less so in post-traumatic/
injury CRPS.
3.7. Anticonvulsants
The use of anticonvulsants is based on the assumption that
pain in CRPS may be (at least in part) neuropathic. Antic-
onvulsants (gabapentin, pregabalin) with proven analgesic
effects in other neuropathic pain syndromes, might be
beneﬁcial in pain control. One high-quality RCT investigated
the effect of gabapentin (1800 mg/daily given over 3 weeks) in a
double-blind randomized crossover trial involving 46 patients
with chronic CRPS. There were no differences in pain scores
(the primary outcome measure in the trial) between the
treatment and control groups. However, using global perceived
pain relief, more patients receiving gabapentin reported an
improvement in pain control [40]. It is noticeable that
gabapentin dose that was used (1800 mg/daiy) is not the
maximum (2400 mg/day) recommended for the treatment of
neuropathic pain.
There is moderate evidence for the effectiveness of
gabapentin reducing some of the pain symptoms (including
hyperaesthesia and allodynia) in CRPS patients. Although
frequently used, anticonvulsants appear not to be particularly
useful in clinical practice.3.8. Physiotherapy (various types)
Various methods of physiotherapy are recommended as part
of the multimodal treatment of CRPS. It seems obvious that
exercises are beneﬁcial in restoration of ranges of motion,
strength and in improving function of the affected hand.
However, the underlying mechanisms of physical therapy in
pain control remain obscure. There are several theories
explaining this, including release of endorphins in the central
nervous system, stimulation of sensory nerve endings of
peripheral afferent nerves, spinal cord-mediated analgesia
and anti-inﬂammatory effects. Graded motor imagery (GMI)
and mirror therapy may reduce pain and increase mobility by
ameliorating maladaptive somatosensory and motor cortex
reorganization [41,42]. In general, physiotherapy is aimed at
better adaptation to pain, improving posture, movement,
activities of daily living and psychosocial functioning [43].
Eighteen RCTs have investigated the effect of various
(dozens) kinds of physiotherapy involving a total of 739
patients with acute and chronic CRPS. They treated a mean of
41 (range 13–135) patients per study [8]. Two broadly similar
types of rehabilitation, graded motor imagery (6 week
programme) and mirror therapy (4 week programme) might
be useful for reducing the pain and disability associated with
post-traumatic and post-stroke CRPS. This beneﬁcial effect has
been maintained up to 6 months after therapy [41–45].
However only the patients following uncomplicated distal
radial fractures with early CRPS had proven beneﬁt. The two
low-quality trials were conducted in the same centre setting
[41,42]; the effectiveness of this therapy has not been
reproduced by other studies. The two low-quality RCTs
involving 72 patients with early post-stroke CRPS investigated
the effect of mirror therapy vs placebo (covered mirror). At a
mean follow-up of 6 months, a meaningful reduction of pain
and functional improvement were seen in the treatment
groups [44,45].
Oerlemans et al. employed multimodal physiotherapy in
the treatment of 135 patients with CRPS lasting <12 months.
After initial drug therapy with free radical scavengers (DMSO
or N-acetylcysteine), vasodilators and trigger point lidocaine
injections, the patients were randomized to physiotherapy,
occupational therapy or minimal ‘‘social work’’ intervention
(control therapy). After a mean follow-up of one year, no
signiﬁcant differences were observed in the reduction of pain
or improvement of function between the three groups [43].
There is no convicting evidence supporting the effectiveness
of other physiotherapy treatments [8].
There is moderate evidence of effectiveness of GMI and
mirror therapy in CRPS, however, a type II error is likely to be
present. Physiotherapy in general is likely to have a positive
effect on the impairment level in patients with chronic CRPS
but less effect on pain reduction. It is commonly accepted as a
part of the standard treatment of CRPS.
3.9. Spinal cord stimulation
This therapy is based on the assumption that electrical
stimulation of the spinal cord (SCS) engenders spinal cord-
mediated analgesia and anti-inﬂammatory effects [46]. One
low-quality RCT studied the use of spinal cord stimulation and
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chronic CRPS; these patients have been reported further at
follow-ups of 2 and 5 years [47]. At follow-up of 2 years,
statistically signiﬁcant differences were noted in pain scores
and seven-point global perceived effect scale, favouring the
treatment group. No differences were found for the changes in
functional status and quality of life [47]. At 5 years follow-up
the difference between the intervention and control groups
was lost [48].
There is moderate evidence for the effectiveness of the
spinal cord stimulation in giving some reduction in pain
symptoms in CRPS patients. SCS has no effect on function, it is
an invasive procedure and its effect is unpredictable and
appears only to be temporary. Regardless it enjoys increasing
popularity, particularly for patients with chronic CRPS and has
been recommended by the National Institute for Clinical
Effectiveness (NICE) in the UK, which has a reasonably high bar
to acceptance.
3.10. Ketamine
The use of ketamine for the treatment of CRPS is based the role
of glutaminergic N-methyl-D-aspartate receptor (NMDA) in
the process of ‘‘sensitization’’ in the central nervous system.
There is some evidence that ketamine has strong NMDA-
receptor blocking (antagonist) properties resulting in inhibi-
tion of the central sensitization mechanism. Three low-level
RCTs have investigated the effect of intravenous (two studies;
60 and 19 patients) or topical (one trial; 20 patients) ketamine,
involving patients with acute and chronic CRPS [9]. Two
studies showed statistically signiﬁcant differences in pain
relief, favouring the treatment (i.v. ketamine) groups. This
effect was, however, transient: the lowest pain scores were one
week after the ketamine treatment. No positive effect on
function was observed. In one study, the application of topical
10% ketamine did not lead to pain relief but it reduced
allodynia. The level of evidence of these studies was 2B,
suggesting only a weak recommendation and moderate-
quality evidence for the use of ketamine in the treatment of
CRPS [9].
Regardless of this conclusion, i.v. ketamine treatment
enjoys increasing popularity, particularly for patients with
chronic CRPS, resistant to any other therapy. It offers at least
temporary relief from severe, debilitating pain, however it
does not improve the function of the affected limb.
3.11. Fentanyl
Opioid drugs, including fentanyl, are commonly used to treat
neuropathic pain and are considered effective. There is some
evidence that pain in CRPS may have, at least in part, a
neuropathic component [49]. One study has investigated the
effect of fentanyl in patients suffering from various types of
neuropathic pain, including postherpetic neuralgia, chronic
postoperative pain and CRPS. Transdermal fentanyl (one-day
fentanyl patch) was titrated over 10–29 days to establish the
maximum tolerated and effective dose (12.5–50 mg/h). One
hundred and sixty three patients who responded to this
therapy were then entered into a randomized withdrawal
phase. The number of participants completing the study was47/84 (56%) with fentanyl and 28/79 (35%) with placebo. Nearly
60% of participants taking fentanyl were satisﬁed and very
satisﬁed with their treatment at the end of the study,
compared with about 40% with placebo [50]. There is
insufﬁcient evidence to support or refute the suggestion that
fentanyl works for any neuropathic pain condition.
3.12. Amputation
Amputation of the limb is a deﬁnitive treatment that may be
considered in so-called ‘‘end-stage’’ CRPS. Fortunately this is
seen rarely. In this long-standing, therapy-resistant disease,
apart from intractable, debilitating pain, several new problems
may be encountered such as a totally dysfunctional limb,
severe recurrent infections and chronic trophic ulcers.
Therefore amputation of the limb may be appropriate for
pain relief and improving patients' quality of life. Twenty-six
studies, involving 111 amputations in 107 patients have
investigated the effect of amputation on pain relief and
patients' satisfaction. None of these 26 studies was an RCT.
The primary reasons cited for amputation were pain (80%) or a
dysfunctional limb (72%). Recurrence of CRPS in the stump was
reported in twelve studies and occurred in 31 of 65 patients
(48%); phantom pain occurred in ﬁfteen patients (23%). Thirty-
six patients were ﬁtted with prostheses; 14 of these patients
used the prosthesis. Patient satisfaction was reported in eight
studies, but the nature of the satisfaction was not clearly
explained. Changes in patient quality of life were reported in
three studies (15 patients): quality of life improved in ﬁve
patients and the joy of life improved in another six patients
[51]. Available evidence does not clearly delineate the
beneﬁcial and adverse effects of an amputation for long-
standing, therapy-resistant CRPS. Whether to amputate or not
remains an unanswered question.
3.13. Vitamin C for prevention CRPS
Vitamin C has been suggested as a low-risk intervention that
might limit excessive soft tissue injury and prevent CRPS. The
mechanism of action of vitamin C is thought to be by inhibiting
local inﬂammatory cascades via antioxidant mechanisms.
Four high-quality RCTs have investigated the effect of vitamin
C for preventing the development of CRPS. The studies
compared vitamin C with placebo in a total of 1081 patients
following distal radial fractures (the studies assessed 123, 195,
427 and 336 patients respectively) [52–55]. All four trials
included predominantly older women and a mix of intra- and
extra-articular fractures of the distal radius. In two trials,
patients were treated with operative and nonoperative
techniques, whereas the two other trials included only
nonoperative management. In two trials patients were
randomized to 500 mg of vitamin C daily for 50 days vs
placebo (1:1), in one study a dose of 1000 mg of vitamin C was
used in the same manner, whereas one randomized patients
to 200, 500, or 1500 mg of vitamin C daily for 50 days vs placebo
(3:1). All studies showed a statistically signiﬁcant reduction in
CRPS incidence in groups receiving vitamin C vs placebo at a
follow-up of one year. Therefore, a general conclusion from
these studies is that it is likely that oral administration of 500–
1000 mg of vitamin C per day for 50 days from the date of the
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distal radial fractures. Following this conclusion, it is fre-
quently used in clinical practice and is also recommended by
the American Association of Orthopedic Surgery for patients
following distal radial fractures [56].
However, all of the studies have numerous limitations,
including:
(a) use of non-Budapest criteria of diagnosis of CRPS, instead
using the older criteria of Veldman et al. and Atkins et al.
[57,58];
(b) two of the studies had statistically signiﬁcant dichotomous
primary outcomes and their fragility indices were each one
event or fewer [52,53];
(c) all studies reported surprisingly high incidence of CRPS in
the control groups of 10–12%, at a mean follow-up of one
year, suggesting use of invalid diagnostic criteria; and
(d) there were 103 patients lost to follow-up across the four
trials. The scenario in which all missing patients were
assumed to have CRPS is improbable, but it is equally
improbable that none of these patients developed CRPS, as
was assumed in these studies. Bearing in mind above
limitations, the most recent systematic review by Evaniew
et al. suggests that the literature is conﬂicting and fails to
demonstrate a statistically signiﬁcant effect for vitamin C
in preventing CRPS in patients with distal radius fractures
[59].
4. Discussion
The review of RCTs showed that only bisphosphonates were
found to give uniformly statistically signiﬁcant effects over
placebo but the studies were not high quality. Some
improvement has been reported with topical DMSO, systemic
steroids, spinal cord stimulation and graded motor imagery/
mirror therapy programmes. The available evidence does not
support the use of other treatments in CRPS. This conclusion is
typical and common for many meta-analyses in this topic.
This may prompt one to reﬂect that there is a lack of good
evidence for or against any treatment of CRPS and lead to
therapeutic nihilism.
As mentioned in the introduction, CRPS comprises a
broad spectrum of clinical forms which may be driven by
different pathophysiological mechanisms. The degree to
which individual mechanisms contribute to CRPS may differ
between patients and even within one patient over time
[5,49,60]. These facts may explain the difﬁculty in achieving
an evidence-based treatment of CRPS. These studies suggest
that there is not and cannot be one, universal treatment for
all forms of CRPS; rather treatment should be targeted to the
particular  clinical manifestation (i.e. different for early or
for chronic CRPS).
Clinically appreciable CRPS is a rare disease, therefore, it is
difﬁcult to recruit large numbers of patients to conduct a
randomized study. Likewise, it is difﬁcult to select patients
with uniform disease pattern in order to avoid a heteroge-
neous patient population, typical of many studies which
further biases the results of the clinical trials [7,60].In addition the studies use heterogeneous primary out-
come measures, e.g. some are focused on pain, other on
improvement of function. It is very uncommon to use
‘‘recovery from CRPS’’ as a primary outcome measure because
full recovery is rare and there is also no commonly accepted
deﬁnition of recovery.
The review of RCTs showed that only bisphosphonates
were found to give uniformly positive effects, statistically
signiﬁcantly better than placebo. Improvement has been
reported with topical DMSO, systemic steroids, spinal cord
stimulation and graded motor imagery/mirror therapy pro-
grammes. The available evidence does not support the use of
other treatments in CRPS, however they are frequently used in
clinical practice. This discrepancy shows that available
evidence does not necessarily reﬂect what is truly effective
and what is sham in the management of CRPS.
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